Managing Drug Interactions with Direct Oral Anticoagulants

Course #95011 - $15-


Self-Assessment Questions

    1 . Which is important to keep in mind regarding drug transporter systems (e.g., P-glycoprotein [P-gp])?
    A) These proteins can affect pharmacokinetics.
    B) Breast cancer resistance protein moves drugs into the liver.
    C) Most available data are related to organic anion transporting polypeptides.
    D) It is rare for medications to impact P-gp and CYP450.

    REVIEW OF CYP450 AND TRANSPORTER INTERACTIONS

    Pharmacokinetics can also be affected by drug transporters (e.g., P-glycoprotein, breast cancer resistance protein [BCRP], multidrug and toxin excluders [MATEs], organic anion transporting polypeptides [OATPs]). All of these proteins help move medications into or out of cells, which can impact drug absorption, distribution, or elimination [3; 5].

    Click to Review



    2 . Which drug transport system has the most available data related to its effects on drug pharmacokinetics?
    A) BCRP
    B) MATEs
    C) OATPs
    D) P-gp

    REVIEW OF CYP450 AND TRANSPORTER INTERACTIONS

    We are still learning about the significance of these transporters on pharmacokinetics. Most of the available data are related to P-glycoprotein (P-gp, multidrug resistance protein 1 [MDR1]). P-gp is a drug efflux pump found in the gut, liver, kidney, blood-brain barrier, and cancer cells. It pumps drugs out of cells and into the gut, bile, and/or urine for excretion [6]. Other examples include BCRP, which pumps drugs out of cells in the gut, liver, and kidney, and OATPs (e.g., OATP1B1, OATP1B3), which move drugs into the liver [5].

    Click to Review



    3 . Which pair of direct oral anticoagulants are significantly metabolized by CYP3A4?
    A) Apixaban and dabigatran
    B) Edoxaban and rivaroxaban
    C) Apixaban and rivaroxaban
    D) Edoxaban and dabigatran

    REVIEW OF CYP450 AND TRANSPORTER INTERACTIONS

    Generally, CYP450 interactions and drug transporter interactions involve substrates, inhibitors, and inducers. Inhibitors may increase levels of CYP450 or P-gp substrates, and inducers may decrease levels of CYP450 or P-gp substrates. For many interactions, CYP450 enzyme inhibition or induction is also involved, and P-glycoprotein substrates are often also CYP3A4 substrates, so the contribution of P-gp inhibition/induction versus CYP450 inhibition/induction can be difficult to discern [7,8,9]. For example, apixaban and rivaroxaban are metabolized by CYP3A4 (Table 1), and absorption of all DOACs is affected by P-glycoprotein (Table 2) [2,10].

    Click to Review



    4 . Which of the following medications is a strong inhibitor of CYP3A4?
    A) Nafcillin
    B) Oxcarbazepine
    C) Rifabutin
    D) Voriconazole

    REVIEW OF CYP450 AND TRANSPORTER INTERACTIONS

    SELECT CYP450-3A4 PATHWAY DRUG INTERACTIONS

    DOAC SubstratescSelect InhibitorsSelect Inducers
    Apixaban
    Rivaroxaban
    Amiodarone
    Amlodipine
    Aprepitanta
    Ceritinibb
    Cimetidine
    Ciprofloxacina
    Clarithromycinb
    Crizotiniba
    Cyclosporine
    Diltiazema
    Dronedaronea
    Erythromycina
    Ethinyl estradiol
    Fluconazolea
    Fluoxetine
    Fluvoxamine
    Grapefruita
    Idelalisibb
    Imatiniba
    Isavuconazoniuma
    Isoniazid
    Itraconazoleb
    Ketoconazoleb
    Letermovira
    Levoketoconazoleb
    Mifepristone
    Nefazodoneb
    Netupitant/palonosetrona
    Nicardipine
    Nirmatrelvir/ritonavirb
    Posaconazoleb
    Ticagrelor
    Verapamila
    Voriconazoleb
    Apalutamide
    Bosentan
    Carbamazepine
    Dexamethasone
    Enzalutamide
    Fosphenytoin
    Lorlatinib
    Modafinil
    Nafcillin
    Oxcarbazepine
    Phenobarbital
    Phenytoin
    Primidone
    Rifabutin
    Rifampin
    Rifapentine
    St. John's wort
    Topiramate
    aModerate inhibitors (≥2 to <5-fold increase in exposure, or 50% to 80% decrease in clearance of substrate). For many medications, strength of inhibition in vivo is undetermined.
    bStrong inhibitors (≥5-fold increase in exposure or >80% decrease in clearance of substrate).
    cDabigatran is not a substrate, inducer, or inhibitor of CYP450 enzymes. Edoxaban is only minimally metabolized by CYP450.
    Click to Review



    5 . Which of the following medications is a strong inducer of P-gp?
    A) Amiodarone
    B) Diltiazem
    C) Erythromycin
    D) Phenytoin

    REVIEW OF CYP450 AND TRANSPORTER INTERACTIONS

    SELECT P-GLYCOPROTEIN DRUG INTERACTIONS

    DOAC SubstratesSelect InhibitorsSelect Inducersa
    Apixaban
    Dabigatran
    Edoxaban
    Rivaroxaban
    Amiodarone (moderate or strong inhibitor)
    Atorvastatin
    Azithromycin
    Canagliflozin (weak inhibitor)
    Captopril
    Carvedilol
    Clarithromycinc (strong inhibitor)
    Cyclosporine (strong inhibitor)
    Diltiazemb
    Dronedaroneb (strong inhibitor)
    Erythromycinb (strong inhibitor)
    Fluconazole
    Grapefruit
    Isavuconazoniumb
    Itraconazolec
    Ketoconazolec (strong inhibitor)
    Lopinavir/ritonavirc
    Lovastatin
    Mirabegron
    Nelfinavirc
    Nirmatrelvir/ritonavirc
    Omeprazole
    Posaconazolec
    Propafenone
    Quinidine (strong inhibitor)
    Quinine
    Ranolazine
    Saquinavir/ritonavirc
    Simvastatin
    Tacrolimus
    Ticagrelor
    Tipranavir/ritonavirc
    Verapamilb (strong inhibitor)
    Vilazodone
    Apalutamide
    Carbamazepine
    Dexamethasone
    Phenobarbital
    Phenytoin/fosphenytoin
    Rifampin
    St. John's wort
    aAll are strong inducers.
    bModerate CYP3A inhibitors
    cStrong CYP3A inhibitors
    Click to Review



    6 . Which medication is most likely to decrease levels of a DOAC and increase thrombosis risk?
    A) Rifampin
    B) Ritonavir
    C) Ranolazine
    D) Famotidine

    MANAGING DOAC INTERACTIONS

    Drug experts from Pharmacist's Letter and Prescriber Insights provide the following practical approach to managing DOAC interactions [11]:

    • Pinpoint critical DOAC interactions, and act if necessary.

    • Generally avoid combining DOACs with strong CYP3A4 and P-glycoprotein inducers (e.g., phenytoin, rifampin, St. John's wort). These may lower DOAC levels and increase thrombosis risk.

    • If these interacting medications cannot be avoided, switch to warfarin, because it is easier to monitor than a DOAC.

    • Watch for strong CYP3A4 and P-glycoprotein inhibitors (e.g., ritonavir, itraconazole), as these may raise DOAC levels and increase bleeding risk.

    Click to Review



    7 . Which of the following medications is most likely to raise levels of a direct oral anticoagulant (DOAC) and increase bleeding risk?
    A) Itraconazole
    B) Levofloxacin
    C) Phenytoin
    D) Famotidine

    MANAGING DOAC INTERACTIONS

    Drug experts from Pharmacist's Letter and Prescriber Insights provide the following practical approach to managing DOAC interactions [11]:

    • Pinpoint critical DOAC interactions, and act if necessary.

    • Generally avoid combining DOACs with strong CYP3A4 and P-glycoprotein inducers (e.g., phenytoin, rifampin, St. John's wort). These may lower DOAC levels and increase thrombosis risk.

    • If these interacting medications cannot be avoided, switch to warfarin, because it is easier to monitor than a DOAC.

    • Watch for strong CYP3A4 and P-glycoprotein inhibitors (e.g., ritonavir, itraconazole), as these may raise DOAC levels and increase bleeding risk.

    Click to Review



    8 . Which of the following statements regarding DOAC interactions with nirmatrelvir/ritonavir is TRUE?
    A) All DOACs should be held during treatment with nirmatrelvir/ritonavir.
    B) Nirmatrelvir/ritonavir may be a concern with DOACs because it inhibits CYP3A4 and P-gp.
    C) DOAC doses should generally be increased during treatment with nirmatrelvir/ritonavir.
    D) Nirmatrelvir/ritonavir may be a concern with DOACs because it induces CYP1A2 and P-gp.

    MANAGING DOAC INTERACTIONS

    To manage these drug interactions, consider the specific DOAC, dose, and indication (Table 3). One example that blends consideration of these factors is use of nirmatrelvir/ritonavir for treatment of COVID-19 in patients receiving a DOAC. This combination introduces potential risk for drug interactions, because ritonavir is a strong CYP3A4 and P-glycoprotein inhibitor. For instance, when a patient is receiving nirmatrelvir/ritonavir for COVID-19, apixaban being given for atrial fibrillation should be reduced by 50% (e.g., from 5 mg to 2.5 mg twice per day) during treatment and for three days after; if the patient is already taking 2.5 mg twice per day, coadministration should be avoided. In contrast, coadministration of nirmatrelvir/ritonavir and rivaroxaban should be avoided [12].

    Click to Review



    9 . What is advised for patients receiving apixaban for venous thromboembolism treatment if a strong CYP3A4 and P-gp inducer is required?
    A) Reduce the apixaban dose by 50%.
    B) Change apixaban to rivaroxaban.
    C) Change apixaban to warfarin.
    D) Continue apixaban at the standard dose.

    MANAGING DOAC INTERACTIONS

    Drug experts from Pharmacist's Letter and Prescriber Insights provide the following practical approach to managing DOAC interactions [11]:

    • Pinpoint critical DOAC interactions, and act if necessary.

    • Generally avoid combining DOACs with strong CYP3A4 and P-glycoprotein inducers (e.g., phenytoin, rifampin, St. John's wort). These may lower DOAC levels and increase thrombosis risk.

    • If these interacting medications cannot be avoided, switch to warfarin, because it is easier to monitor than a DOAC.

    • Watch for strong CYP3A4 and P-glycoprotein inhibitors (e.g., ritonavir, itraconazole), as these may raise DOAC levels and increase bleeding risk.

    Click to Review



    10 . What is generally advised for patients receiving apixaban for stroke prevention in atrial fibrillation and aspirin for cardiovascular primary prevention?
    A) Continue apixaban and aspirin.
    B) Stop aspirin.
    C) Change aspirin to clopidogrel.
    D) Reduce the apixaban dose by 50%.

    MANAGING DOAC INTERACTIONS

    Caution should be exercised when prescribing a DOAC with medications that increase the risk of bleeding (e.g., antiplatelets, nonsteroidal anti-inflammatory drugs [NSAIDs], SSRIs/SNRIs). Ensuring the need for both agents is the first step. For example, aspirin used for cardiovascular primary prevention can usually be discontinued; aspirin for cardiovascular primary prevention is no longer routinely recommended, regardless of DOAC use [4; 13; 14]. Duration of combination therapy is another concern. For instance, clopidogrel can be discontinued one year after stent placement for most patients with atrial fibrillation on a long-term DOAC. Randomized trial data (e.g., AFIRE, EPIC-CAD) support oral anticoagulant monotherapy after this point in patients with atrial fibrillation and stable coronary artery disease, and current guidelines support discontinuing antiplatelet therapy for most of these patients [15; 17; 18; 19].

    Click to Review